The World Health Organization (WHO) has recommended prioritizing the Ervebo vaccine for a randomized clinical trial to combat the ongoing Bundibugyo virus outbreak in the Democratic Republic of Congo (DRC). While Ervebo was originally designed to target the Ebola Zaire virus, preliminary animal study data suggest it may offer cross-protection against the Bundibugyo strain, specifically by reducing mortality rates.
Vaccine Prioritization and Clinical Trial Strategy
The WHO Technical Advisory Group on Candidate Vaccine Prioritisation issued the recommendation following a meeting on July 31. According to the WHO, the group previously advised against using Ervebo outside of research settings because its efficacy against the Bundibugyo virus remained unproven. However, new evidence from animal studies shifted this stance, leading experts to call for a formal clinical trial to definitively measure the vaccine’s performance against this specific virus.
Did you know?
The Bundibugyo virus is one of six known species of Orthoebolavirus. It was first identified during an outbreak in Uganda in 2007 and typically carries a case fatality rate between 30% and 50%, according to WHO data.
Context of the DRC Outbreak
The current outbreak, declared on May 15, 2026, has resulted in 3,605 confirmed cases and 1,587 deaths as of July 30, according to official WHO reporting. Gavi, the Vaccine Alliance, notes that the virus has also crossed into Uganda. On May 17, 2026, the WHO designated the situation a Public Health Emergency of International Concern (PHEIC), the highest level of alert available under international regulations.
Because there is currently no licensed vaccine or specific treatment for the Bundibugyo virus, response teams have relied on traditional public health measures. These include rapid case detection, isolation, contact tracing, and the implementation of safe burial practices, as reported by Gavi.
Safety and Research Requirements
While the advisory group identified no immediate safety concerns regarding the use of Ervebo among individuals who had contact with confirmed cases, they cautioned that the vaccine’s ability to prevent transmission is not yet established. The WHO maintains that a vaccine developed specifically for the Bundibugyo virus remains the preferred long-term solution. Currently, no such candidate vaccine has provided sufficient preliminary data for clinical use.
Health authorities emphasize that until a vaccine is proven effective, community engagement and infection control remain the primary tools for limiting the spread of the Bundibugyo virus in fragile or conflict-affected regions.
Frequently Asked Questions
Is Ervebo an approved treatment for the Bundibugyo virus?
No. Ervebo is licensed for the Ebola Zaire virus. It is currently being prioritized for research trials to determine if it provides cross-protection against the Bundibugyo strain.
How is the Bundibugyo virus transmitted?
According to Gavi, it spreads through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals, as well as contact with contaminated surfaces.
Why is this outbreak considered high risk?
The virus is rare and difficult to detect with standard rapid field tests. Furthermore, the outbreak is occurring in a conflict-affected region, which complicates access to diagnostics and medical care.
Stay informed on the latest developments in global health. Subscribe to our newsletter for updates on vaccine research and outbreak responses, or explore our archive for more in-depth reporting on emerging infectious diseases.
Worth a look